Cargando…
Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product
BACKGROUND: Data on short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilar utilization from claims data in the USA are limited. OBJECTIVE: To evaluate patient baseline characteristics and utilization patterns for short-acting G-CSF products with particular focus on the ass...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847294/ https://www.ncbi.nlm.nih.gov/pubmed/33517548 http://dx.doi.org/10.1007/s40801-021-00228-9 |
_version_ | 1783644902600474624 |
---|---|
author | Mendelsohn, Aaron B. Marshall, James McDermott, Cara L. Pawloski, Pamala A. Brown, Jeffrey S. Lockhart, Catherine M. |
author_facet | Mendelsohn, Aaron B. Marshall, James McDermott, Cara L. Pawloski, Pamala A. Brown, Jeffrey S. Lockhart, Catherine M. |
author_sort | Mendelsohn, Aaron B. |
collection | PubMed |
description | BACKGROUND: Data on short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilar utilization from claims data in the USA are limited. OBJECTIVE: To evaluate patient baseline characteristics and utilization patterns for short-acting G-CSF products with particular focus on the assessment of filgrastim biosimilar usage relative to the originator product. PATIENTS AND METHODS: We examined filgrastim, filgrastim-sndz, and tbo-filgrastim use among adult patients between January 2012 and March 2019 across the five health-plan research partners in the BBCIC Distributed Research Network. The publicly available Sentinel System analytic toolkit was used to perform the distributed analyses. RESULTS: We evaluated over 38 million eligible health-plan members representing more than 88 million person-years of data. We identified 45,204 incident treatment episodes, including 33,118 episodes with filgrastim, 6525 episodes with filgrastim-sndz, and 5,561 episodes with tbo-filgrastim. We observed that the demographic and clinical characteristics of users were comparable across products. While total use of all filgrastim products remained consistent, the proportion of incident episodes of the originator filgrastim steadily decreased since 2014, with filgrastim-sndz and tbo-filgrastim making up the difference. Utilization for the G-CSF biosimilar, filgrastim-sndz, increased from 40 (1%) of 6823 total filgrastim product episodes in 2015, to 2486 (44%) of a total 5668 episodes of filgrastim products in 2018 (partial data for 2018). CONCLUSION: New episodes of short-acting biosimilar filgrastim products have increased over time while the overall number of new users remained flat. Although barriers to biosimilar use in oncology have been noted, uptake has begun and continues to grow. |
format | Online Article Text |
id | pubmed-7847294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-78472942021-02-01 Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product Mendelsohn, Aaron B. Marshall, James McDermott, Cara L. Pawloski, Pamala A. Brown, Jeffrey S. Lockhart, Catherine M. Drugs Real World Outcomes Short Communication BACKGROUND: Data on short-acting recombinant granulocyte colony-stimulating factor (G-CSF) biosimilar utilization from claims data in the USA are limited. OBJECTIVE: To evaluate patient baseline characteristics and utilization patterns for short-acting G-CSF products with particular focus on the assessment of filgrastim biosimilar usage relative to the originator product. PATIENTS AND METHODS: We examined filgrastim, filgrastim-sndz, and tbo-filgrastim use among adult patients between January 2012 and March 2019 across the five health-plan research partners in the BBCIC Distributed Research Network. The publicly available Sentinel System analytic toolkit was used to perform the distributed analyses. RESULTS: We evaluated over 38 million eligible health-plan members representing more than 88 million person-years of data. We identified 45,204 incident treatment episodes, including 33,118 episodes with filgrastim, 6525 episodes with filgrastim-sndz, and 5,561 episodes with tbo-filgrastim. We observed that the demographic and clinical characteristics of users were comparable across products. While total use of all filgrastim products remained consistent, the proportion of incident episodes of the originator filgrastim steadily decreased since 2014, with filgrastim-sndz and tbo-filgrastim making up the difference. Utilization for the G-CSF biosimilar, filgrastim-sndz, increased from 40 (1%) of 6823 total filgrastim product episodes in 2015, to 2486 (44%) of a total 5668 episodes of filgrastim products in 2018 (partial data for 2018). CONCLUSION: New episodes of short-acting biosimilar filgrastim products have increased over time while the overall number of new users remained flat. Although barriers to biosimilar use in oncology have been noted, uptake has begun and continues to grow. Springer International Publishing 2021-01-30 /pmc/articles/PMC7847294/ /pubmed/33517548 http://dx.doi.org/10.1007/s40801-021-00228-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Short Communication Mendelsohn, Aaron B. Marshall, James McDermott, Cara L. Pawloski, Pamala A. Brown, Jeffrey S. Lockhart, Catherine M. Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product |
title | Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product |
title_full | Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product |
title_fullStr | Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product |
title_full_unstemmed | Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product |
title_short | Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product |
title_sort | patient characteristics and utilization patterns of short-acting recombinant granulocyte colony-stimulating factor (g-csf) biosimilars compared to their reference product |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847294/ https://www.ncbi.nlm.nih.gov/pubmed/33517548 http://dx.doi.org/10.1007/s40801-021-00228-9 |
work_keys_str_mv | AT mendelsohnaaronb patientcharacteristicsandutilizationpatternsofshortactingrecombinantgranulocytecolonystimulatingfactorgcsfbiosimilarscomparedtotheirreferenceproduct AT marshalljames patientcharacteristicsandutilizationpatternsofshortactingrecombinantgranulocytecolonystimulatingfactorgcsfbiosimilarscomparedtotheirreferenceproduct AT mcdermottcaral patientcharacteristicsandutilizationpatternsofshortactingrecombinantgranulocytecolonystimulatingfactorgcsfbiosimilarscomparedtotheirreferenceproduct AT pawloskipamalaa patientcharacteristicsandutilizationpatternsofshortactingrecombinantgranulocytecolonystimulatingfactorgcsfbiosimilarscomparedtotheirreferenceproduct AT brownjeffreys patientcharacteristicsandutilizationpatternsofshortactingrecombinantgranulocytecolonystimulatingfactorgcsfbiosimilarscomparedtotheirreferenceproduct AT lockhartcatherinem patientcharacteristicsandutilizationpatternsofshortactingrecombinantgranulocytecolonystimulatingfactorgcsfbiosimilarscomparedtotheirreferenceproduct |